IDL Diagnostics AB (publ) (STO:IDLDX)
Sweden · Delayed Price · Currency is SEK 0.4140
+0.0160 (4.02%)
Aug 27, 2026, 4:40 PM CET
IDL Diagnostics AB Revenue
IDL Diagnostics AB had revenue of 14.56M SEK in the quarter ending June 30, 2026, with 43.51% growth. This brings the company's revenue in the last twelve months to 58.95M, up 7.55% year-over-year. In the year 2025, IDL Diagnostics AB had annual revenue of 53.11M, down -7.54%.
Revenue (ttm)
58.95M
Revenue Growth
+7.55%
P/S Ratio
1.56
Revenue / Employee
2.36M
Employees
25
Market Cap
91.68M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 53.11M | -4.33M | -7.54% |
| Dec 31, 2024 | 57.44M | 14.40M | 33.45% |
| Dec 31, 2023 | 43.04M | 6.05M | 16.37% |
| Dec 31, 2022 | 36.99M | 24.99M | 208.32% |
| Dec 31, 2021 | 12.00M | 11.91M | 14,180.95% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Getinge AB | 34.24B |
| Swedish Orphan Biovitrum AB | 30.62B |
| Medicover AB | 27.33B |
| Sectra AB | 3.65B |
| Spago Nanomedical AB | 3.81M |
| Immunovia AB | 1.21M |
| Prostatype Genomics AB | 594.00K |
| OncoZenge AB | 71.00K |
IDL Diagnostics AB News
- 7 days ago - IDL Diagnostics AB Quarterly report: Q2 2026 - Filings
- 3 months ago - IDL Diagnostics AB Quarterly report: Q1 2026 - Filings
- 6 months ago - IDL Diagnostics AB Quarterly report: Q4 2025 - Filings
- 6 months ago - IDL Diagnostics AB Annual report: Q4 2025 - Filings
- 10 months ago - IDL Diagnostics AB Quarterly report: Q3 2025 - Filings